Base de dados : LILACS
Pesquisa : C20.111 [Categoria DeCS]
Referências encontradas : 858 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 86 ir para página                         

  1 / 858 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1285647
Autor: Jiang, Tian-Fang; Zheng, Jia; Chen, Xu.
Título: Subacute combined degeneration of the spinal cord with concomitant autoimmune disease: report of 2 cases
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;54(10):e11355, 2021. graf.
Idioma: en.
Resumo: The etiology of subacute combined degeneration (SCD) of the spinal cord is closely associated with vitamin B12 (VitB12) deficiency. The clinical manifestations of SCD are complex and vary substantially. Due to some SCD patients with atypical manifestations and concomitant autoimmune disorders, the probability of misdiagnosis and missed diagnosis is still relatively high in the early stage. We report the cases of two patients who were missed or misdiagnosed at another hospital because of the normal initial VitB12 level and partial overlap of clinical manifestations, finally diagnosed as SCD with atypical manifestations and concomitant autoimmune disorders, pharyngeal-cervical-brachial Guillain-Barre syndrome in Case 1 and SCD with autoimmune thyroiditis in Case 2. After undergoing corresponding treatment, death was reported in Case 1 and improvement in Case 2. Analysis of the clinical manifestations and investigation of the underlying pathogenesis in such patients could help improve the rate of early diagnosis and allow timely treatment of SCD, thereby preventing disease progression and poor clinical outcomes.
Descritores: Doenças Autoimunes/complicações
Doenças Autoimunes/diagnóstico
Degeneração Combinada Subaguda/complicações
Degeneração Combinada Subaguda/diagnóstico
Degeneração Combinada Subaguda/patologia
-Medula Espinal
Vitamina B 12
Imageamento por Ressonância Magnética
Limites: Humanos
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  2 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1292505
Autor: Torres, Demetrio; Díaz, Laura; Fernández, Miguel; Arellano, Esteban; Chandía, Mauricio.
Título: Efectividad de Rituximab en el tratamiento de citopenias autoinmunes refractarias en adultos / Effectiveness of Rituximab in the treatment of cytopenias refractory autoimmune in adults
Fonte: Rev. méd. Maule;33(2):20-24, sept. 2018. tab.
Idioma: es.
Resumo: The term autoimmune cytopenias is referred to a heterogeneous group of diseases characterized by a reduced peripheral blood cell counts in one or more cellular series, because an immunological disorder. The first line therapy is steroids, followed by splenectomy or immunesupressant therapy in non-responders. Rituximab is an anti CD20 monoclonal antibody used as a third line in refractory patients or as an alternative to splenectomy. We present a retrospective study of nine patients with autoimmune cytopenias treated in a public hospital setting with rituximab. Five patients with the diagnosis of inmune thrombocytopenic purpura received it, all of them achieved hematological response (4 complete and one partial). The median time to the best response was 6 weeks, staying in this category after 6 months of follow up. Four patients with autoimmune hemolytic anemia received rituximab, three of them achieving partial response and one was lost from follow up. No severe adverse effects related to rituximab were registered.
Descritores: Doenças Autoimunes/tratamento farmacológico
Trombocitopenia/tratamento farmacológico
Anticorpos Monoclonais Murinos/uso terapêutico
Fatores Imunológicos/uso terapêutico
Anemia Hemolítica Autoimune/tratamento farmacológico
Neutropenia/tratamento farmacológico
-Estudos Retrospectivos
Púrpura Trombocitopênica Idiopática/imunologia
Rituximab/administração & dosagem
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Responsável: CL1.1 - Biblioteca Central


  3 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1288210
Autor: Sorrentino, L; Vergel, L; Hamaui, A; Dubinsky, D.
Título: Síndrome autoinmune inducido por inyección cosmética de ácido hialurónico / Autoimmune syndrome induced by cosmetic injection of hyaluronic acid
Fonte: Rev. argent. reumatolg. (En línea);31(4):40-43, dic. 2020. ilus, tab.
Idioma: es.
Resumo: El síndrome autoinmune/inflamatorio inducido por adyuvantes (ASIA) es una condición en la cual la exposición a un adyuvante lleva a una respuesta inmune aberrante dando como resultado signos y síntomas de enfermedades autoinmunes. Se presenta el caso de una paciente con artritis y púrpura palpable luego de inyección labial de ácido hialurónico.

Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) is a condition in which exposure to an adjuvant leads to an aberrant immune response resulting in signs and symptoms of autoimmune diseases. We present the case of a patient with arthritis and palpable purpura after hyaluronic acid lip injection.
Descritores: Vasculite
-Doenças Autoimunes
Adjuvantes Farmacêuticos
Ácido Hialurônico
Responsável: AR423.1 - Biblioteca


  4 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1282356
Autor: Gallo, C; Ramírez, L; Ramos, G; Sepúlveda, D; Pozo, P; Cáceres, N; Vizcarra, G; Fuentealba, C; Godoy, M; Pacheco, D.
Título: Anti TNF como inductor de lupus cutáneo: caso clínico / Anti TNF as inducer of cutaneous lupus: clinical case
Fonte: Rev. chil. reumatol;35(4):158-160, 2019. ilus.
Idioma: es.
Resumo: El mayor acceso a las terapias biológicas para el tratamiento de múltiples enfer-medades autoinmune trae consigo el mayor riesgo de padecer eventos adversos relacionados al uso de estos2,4. Presentamos un caso clínico de una paciente con diagnóstico de artritis reumatoide en tratamiento con ANTI TNF

The greater access to biological therapies for the treatment of multiple autoim-mune diseases brings with it the greatest risk of suffering adverse events related to the use of these (2,4). We present a clinical case of a patient diagnosed with rheumatoid arthritis in treatment with ANTI TNF
Descritores: Lúpus Eritematoso Cutâneo/etiologia
Inibidores do Fator de Necrose Tumoral/efeitos adversos
-Artrite Reumatoide/complicações
Doenças Autoimunes/terapia
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: CL30.1 - Biblioteca


  5 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1179031
Autor: Sadeghi, Mostafa; Zarabadipour, Mahdieh; Azmodeh, Faezeh; Mirzadeh, Monirsadat; Golezari, Ali Sarbazi.
Título: Association of serum level of 25-hydroxy vitamin D with oral lichen planus: a case-control study / Asociación del nivel sérico de 25-hidroxi vitamina D con el liquen plano oral: un estudio de casos y controles
Fonte: J. oral res. (Impresa);9(5):400-404, oct. 31, 2020. tab.
Idioma: en.
Resumo: Introduction: Vitamin D deficiency is a global health problem that can be a risk factor for a broad range of diseases such as some autoimmune diseases. Due to the autoimmune base of lichen planus, it seems that a reduction of the serum level of vitamin D is related to lichen planus. In this study, we investigate the relation between serum level of vitamin D and oral lichen planus patients (OLP). Material and Methods: In this case-control study, 35 patients with OLP (including 15 men and 20 women) and 70 healthy volunteers (including 35 men and 35 women), aged between 30-60 years old, referred to Qazvin University of Medical Sciences were investigated. None of these volunteers had systemic diseases. Vitamin D levels were measured with ELFA (Enzyme Linked Fluorescent Assay) and the data was analyzed using the chi-squared test and t-test. Results: The mean serum level of vitamin D in the control group was 23.7±9ng/ml and in the case group was 18.12±8/7ng/ml. The results show that the serum level of vitamin D in patients with OLP is significantly less than in the control group (p<0.05). Conclusion: According to the results, the serum level of vitamin D in patients with OLP was significantly lower than that of healthy people.

Introducción: La deficiencia de vitamina D es un problema de salud global que puede ser un factor de riesgo para una amplia gama de enfermedades, como algunas enfermedades autoinmunes. Debido a la base autoinmune del liquen plano, parece que una reducción del nivel sérico de vitamina D está relacionada con el liquen plano. En este estudio, investigamos la relación entre el nivel sérico de vitamina D y los pacientes con liquen plano oral (LPO). Material y Métodos: En este estudio de casos y controles, 35 pacientes con LPO (incluidos 15 hombres y 20 mujeres) y 70 voluntarios sanos (incluidos 35 hombres y 35 mujeres), con edades comprendidas entre 30 y 60 años, remitieron a la Universidad de Medicina de Qazvin. Se investigaron las ciencias. Ninguno de estos voluntarios padecía enfermedades sistémicas. Los niveles de vitamina D se midieron con ELFA (ensayo fluorescente ligado a enzimas) y los datos se analizaron utilizando la prueba de chi-cuadrado y la prueba t. Resultados: El nivel sérico medio de vitamina D en el grupo de control fue de 23,7 ± 9 ng / ml y en el grupo de casos fue de 18,12 ± 8/7 ng / ml. Los resultados muestran que el nivel sérico de vitamina D en pacientes con OLP es significativamente menor que en el grupo de control (p<0.05). Conclusión: De acuerdo con los resultados, el nivel sérico de vitamina D en pacientes con LPO fue significativamente menor que en personas sanas.
Descritores: Deficiência de Vitamina D/complicações
Líquen Plano Bucal/etiologia
-Doenças Autoimunes/etiologia
Estudos de Casos e Controles
Distribuição de Qui-Quadrado
Epidemiologia Experimental
Soro
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: CL30.1 - Biblioteca


  6 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1040008
Autor: Parra-Lara, Luis Gabriel; Bojorge Ospina, Cindy Johana; Martínez, Daniela Correa; Pino, Jessica; García-Goez, José Fernando.
Título: Latent tuberculosis infection in patients with autoimmune diseases treated with Infliximab and Etanercept / Infección latente por tuberculosis en pacientes con enfermedades autoinmunes que reciben tratamiento con Infliximab y Etanercept
Fonte: Infectio;23(4):371-375, Dec. 2019. tab, graf.
Idioma: en.
Resumo: Abstract Introduction: Latent tuberculosis infection (LTI) in patients receiving biological therapies is a reality, but this has not been studied in depth in Colombia. Objective: To determine the prevalence of LTI in patients with autoimmune diseases receiving treatment with Infliximab / Etanercept in a referral health center in Cali, Colombia, between the years 2011-2017. Methodology: A retrospective observational study was conducted. We reviewed the 'Registry of patients exposed to tumor necrosis factor-alpha (TNF-α) antagonist drugs in Fundación Valle del Lili'. Patients diagnosed with a chronic inflammatory disease were included who received treatment with Infliximab, Etanercept, or both and followed at least two years. Design: Retrospective observational study. We reviewed the 'Registry of patients exposed to tumor necrosis factor alpha (TNF-α) antagonist drugs in Fundación Valle del Lili'. Patients diagnosed with a chronic inflammatory disease were included who received treatment with Infliximab, Etanercept or both and followed at least a period of 2 years. Results: We included 82 patients; the median age was 47.5 years (IQR=28-60 years), 76% were female, 2% had intimate contact with tuberculosis, 15% were older than 65 years. The 56% had a diagnosis of rheumatoid arthritis as an indication of therapy, and 2% presented infection by hepatitis C virus. The median PPD was 12 mm (IQR=10-17 mm). The prevalence was 3.8% for LTI. Conclusion: The conversion to LTI shows an important prevalence, so it is convenient to perform a routine follow-up of patients receiving therapies with Infliximab and Etanercept.

Resumen Introducción: La infección latente por tuberculosis (ILTB) en pacientes que reciben terapias biológicas es una realidad, pero esto no ha sido estudiado a profundidad en Colombia. Objectivo: Determinar la prevalencia de ILTB en pacientes con enfermedades autoinmunes que reciben tratamiento con Infliximab/Etanercept en una institución de salud de referencia de Cali, Colombia, entre los años 2011-2017. Metodología: Se realizó un estudio observacional retrospectivo. Se revisó el 'Registro de pacientes expuestos a fármacos antagonistas del factor de necrosis tumoral alfa (anti TNF-α) en la Fundación Valle del Lili entre los años 2011 y 2017'. Se incluyeron pacientes con diagnóstico de una enfermedad inflamatoria crónica quienes recibieron tratamiento con Infliximab, Etanercept o ambos y con seguimiento al menos un periodo de 2 años. Resultados: Se incluyeron 82 pacientes; la mediana de edad fue 47,5 años RIC (28-60 años), el 76% fue de sexo femenino, el 2% tuvo contacto íntimo con TB, el 15% era mayor de 65 años. El 56% tenía diagnóstico de artritis reumatoide como indicación de terapia y el 2% presentaba infección por HCV. La mediana de PPD fue 12 mm RIC (10-17 mm). La prevalencia fue del 3,8% para ILTB. Conclusiones: La conversión a ILTB muestra una prevalencia importante, por lo que resulta conveniente la realización de un seguimiento rutinario a los pacientes que reciben terapias con Infliximab y Etanercept.
Descritores: Tuberculose Latente
Infliximab
Etanercepte
Mycobacterium tuberculosis
-Doenças Autoimunes
Terapia Biológica
Colômbia
Estudo Observacional
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: CO359.1 - ACIN - Asociación Colombiana de Infectologia


  7 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-904120
Autor: Posselt, Rayana Taques; Coelho, Vinícius Nicolelli; Pigozzo, Danieli Cristina; Guerrer, Marcela Idalia; Fagundes, Marília da Cruz; Nisihara, Renato; Skare, Thelma Larocca.
Título: Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study
Fonte: Säo Paulo med. j;135(6):535-540, Nov.-Dec. 2017. tab.
Idioma: en.
Resumo: ABSTRACT BACKGROUND: Thyroid autoimmunity is more common in patients with rheumatic diseases than in healthy populations. The degree of association seems subject to influence from patients' geographical location. Here, we aimed to ascertain the prevalence of thyroid autoantibodies in a cohort of patients with systemic rheumatic disease and the degree of association between its presence and inflammatory activity. DESIGN AND SETTING: Cross-sectional observational study in a rheumatology unit. METHODS: 301 patients with systemic lupus erythematosus (SLE), 210 with rheumatoid arthritis (RA), 58 with scleroderma (SSc) and 80 with spondyloarthritis (SpA) were studied regarding thyroid function (TSH and T4), anti-thyroglobulin (TgAb) and anti-thyroperoxidase (TPOab) and compared with 141 healthy controls. Disease activity in patients with rheumatic disease was assessed through appropriate indexes. RESULTS: There were more antithyroid antibodies in SLE patients with hypothyroidism (P = 0.01; odds ratio, OR 2.7; 95% confidence interval, CI: 1.20-6.26) and in those without hypothyroidism (P = 0.06; OR 2.4; 95% CI: 1.28-4.55) than in controls. SSc patients also showed: P = 0.03 both with antithyroid antibodies and hypothyroidism (OR 3.4; 95% CI: 1.06-10.80) and without hypothyroidism (OR 3.1; 95% CI: 1.11-0.13). RA and SpA patients had the same prevalence as controls (P not significant). Presence of autoantibodies with and without hypothyroidism was not associated with the activity or functional indexes evaluated. CONCLUSION: SLE and SSc were associated with higher prevalence of thyroid autoantibodies in patients with and without hypothyroidism, unlike SpA and RA. There was no link between thyroid autoantibody presence and disease activity or functional impairment.
Descritores: Autoanticorpos/sangue
Doenças Autoimunes/sangue
Doenças Reumáticas/sangue
Iodeto Peroxidase/sangue
-Artrite Reumatoide/imunologia
Artrite Reumatoide/sangue
Escleroderma Sistêmico/imunologia
Escleroderma Sistêmico/sangue
Autoanticorpos/imunologia
Estudos de Casos e Controles
Doenças Reumáticas/imunologia
Prevalência
Estudos Transversais
Espondiloartropatias/imunologia
Espondiloartropatias/sangue
Avaliação da Deficiência
Iodeto Peroxidase/imunologia
Lúpus Eritematoso Sistêmico/imunologia
Lúpus Eritematoso Sistêmico/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Tipo de Publ: Estudo Observacional
Responsável: BR1.1 - BIREME


  8 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1144401
Autor: Schult, Sandra; Genaro, Susan; Cajas, Mirella; Ponce, Patricia.
Título: Report of a case of probable overlap between systemic erythematous lupus and polyarteritis nodosa / Reporte de un caso de probable overlap de lupus eritematoso sistémico con panarteritis nudosa
Fonte: Rev. colomb. reumatol;27(1):61-64, 2020. graf.
Idioma: en.
Resumo: ABSTRACT Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a wide range of clinical manifestations that may affect any organ. Polyarteritis nodosa (PAN) is defined as necrotizing inflammatory changes in the medium and small vessels, a rare form of systemic necrotizing vasculitis in childhood. This article discusses the case of a patient with a history of deep venous thrombosis of the left leg, who presented with erythematosus purple lesions in her right hand, associated with pain, intermittent claudication, progressive limping and generalized edema. While in hospital, she was diagnosed with SLE with renal involvement and medium vessel vasculitis mainly of the upper limbs. She also met the criteria for PAN, a rare association that is seldom described in the medical literature.

RESUMEN El lupus eritematoso sistémico (LES) es una enfermedad autoinmune heterogénea con una amplia variedad de manifestaciones clínicas que pueden afectar cualquier órgano. La panarteritis nudosa (PAN) se define como cambios inflamatorios necrotizantes en arterias medianas o pequenas, siendo una vasculitis necrotizante sistêmica rara en la infancia. Presentamos el caso de una paciente con antecedente de trombosis venosa profunda del miembro inferior izquierdo, que presenta lesiones violáceas eritematosas en la mano derecha, asociadas a dolor, claudicación intermitente, limitación funcional progresiva, así como edema generalizado. Durante la hospitalización se llega al diagnóstico de LES con compromiso renal y vasculitis de vasos medianos con predominio de miembros superiores que cumple criterios de PAN, asociación rara muy poco descrita en la bibliografía.
Descritores: Poliarterite Nodosa
Lúpus Eritematoso Sistêmico
-Sinais e Sintomas
Doenças Autoimunes
Limites: Humanos
Feminino
Adolescente
Tipo de Publ: Relatos de Casos
Responsável: CO356.9


  9 / 858 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1144398
Autor: Aragón, Cristian C; Llanos, Julio-Alfredo; Posso-Osorio, Iván; Nieto-Aristizábal, Ivana; Perea-Cardona, Natalia; Ortiz, Andrés-Felipe; Tobón, Gabriel J.
Título: The role of high mobility proteins (HMGB1) in systemic lupus erythematosus / Papel de las proteínas de alta movilidad (HMGB1) en el lupus eritematoso sistémico
Fonte: Rev. colomb. reumatol;27(1):37-45, 2020. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction: The high mobility group box 1 proteins (HMGB1) are non-histone nuclear proteins reported to be present at high levels in some autoimmune diseases, such as systemic lupus erythematosus (SLE). Likewise, in contrast to healthy individuals, patients with SLE have a higher prevalence of anti-HMGB1 antibodies, and these levels have also been associated with heightened disease activity. This article will discuss the involvement of these proteins in immunology, and review the evidence supporting their clinical importance in SLE. Materials and methods: A narrative review was conducted based on a search of the literature up to October 2018, of articles describing the function, structure, prevalence and importance of HMGB1 in different manifestations of SLE. Articles focusing on the presence of HMGB1 and/or its antibodies in patients with SLE or other autoimmune diseases were also reviewed. Results: A total of 69 articles were found. These articles were the foundation to define the structure and functions of HMBG1, including its role as a cytokine released by immune cells in inflammatory processes and necrosis. Additionally, a description of its functions in phagocytosis and NETosis - that have an impact on autoimmune diseases, primarily in SLE - was included. Conclusion: HMGB1 proteins and anti-HMGB1 antibodies are elevated in the serum of patients with SLE, in contrast with healthy individuals or non-severe presentations of the disease; this suggests that they may play a role as a biomarker of disease activity.

RESUMEN Introducción: Las high mobility group box 1 protein (HMGB1, «proteínas de alta movilidad del grupo 1¼) son proteínas nucleares no histonas cuyos niveles se han documentado elevados en ciertas enfermedades autoinmunes, como el lupus eritematoso sistémico (LES). Igualmente, los pacientes con LES presentan una mayor prevalencia de anticuerpos anti-HMGB1 comparados con individuos sanos, al mismo tiempo que se han relacionado sus niveles con una mayor actividad de la enfermedad. En este artículo se revisará la participación de estas proteínas en la inmunología y se abordará la evidencia que sustenta su importancia clínica en el LES. Materiales y métodos: Se realizó una revisión narrativa basada en la búsqueda de la literatura hasta octubre de 2018, de artículos que describieran la función, estructura, prevalencia e importancia de las HMGB1 en diferentes manifestaciones del LES, así como artículos que hayan estudiado la presencia de las HMGB1 o sus anticuerpos en pacientes con LES u otras enfermedades autoinmunes. Resultados: Se encontraron un total de 69 artículos. Con base en ellos definimos la estructura y funciones de las HMBG1, incluyendo su papel como citocina liberada por células inmunes en procesos inflamatorios y en necrosis. Adicionalmente, describimos sus funciones en la fagocitosis y NETosis, que genera implicaciones en enfermedades autoinmunes, principalmente en el LES. Conclusión: Las proteínas HMGB1 y los anticuerpos anti-HMGB1 se encuentran elevados en suero de pacientes con LES comparados con individuos sanos o con formas no severas de la enfermedad, evidenciando que estas pueden comportarse como un biomarcador de actividad de la enfermedad.
Descritores: Proteínas
Proteína HMGB1
-Doenças Autoimunes
Lúpus Eritematoso Sistêmico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CO356.9


  10 / 858 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1138824
Autor: Grupo de Investigación en Medicina InternaLópez-Villegas, Víctor Jaime; Grupo de Investigación en Medicina InternaHincapié Rubio, Luis Miguel; Grupo de Investigación en Medicina InternaRivera, Lina María Saldarriaga.
Título: Life-threatening hemorrhage secondary to acquired deficiency of coagulation factors VIII and XI related to systemic lupus erythematosus: case report / Hemorragia severa secundaria a deficiencia adquirida de factores VIII y XI de la coagulación relacionada con lupus eritematoso sistémico: reporte de caso
Fonte: Rev. colomb. reumatol;26(4):290-293, oct.-dic. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT In patients with autoimmune diseases, the simultaneous occurrence of lupus anticoagulant and blood coagulation factors inhibitors is infrequent and is associated with hemorrhagic events. In these cases, the initial approach requires a thorough interpretation of coagulation laboratory tests and mixing studies to reach a definitive diagnosis. We report the case of a patient with systemic lupus erythematosus and Sjögren's syndrome who presented with hemorrhagic diathesis caused by circulating inhibitors against factors VIII and XI coexisting with lupus anticoagulant. The inhibitors eradication was made with rituximab, achieving good results.

RESUMEN La ocurrencia simultánea de anticoagulante lúpico e inhibidores circulantes contra los factores de la coagulación es infrecuente en los pacientes con enfermedad autoinmune, y está relacionada con eventos hemorrágicos. El abordaje inicial requiere una adecuada interpretación de los tiempos de coagulación y prueba de mezcla con plasma para alcanzar el diagnóstico definitivo. Se reporta el caso de una paciente con lupus eritematoso sistémico y síndrome de Sjögren, quien se presentó con trastorno hemorrágico amenazante de la vida ocasionado por inhibidores circulantes contra los factores VIII y XI de la coagulación en coexistencia con anticoagulante lúpico. El tratamiento de erradicación de los inhibidores se realizó con rituximab, con buenos resultados.
Descritores: Coagulação Sanguínea
Hemorragia
-Doenças Autoimunes
Rituximab
Lúpus Eritematoso Sistêmico
Limites: Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: CO356.9



página 1 de 86 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde